FIG. 5.
Susceptibilities of clinical isolates at baseline and after emergence of I50L substitutions while on treatment with ATV. Susceptibilities (FC) of clinical isolates at baseline (no I50L) (white bars) or after emergence of I50L substitution (black bars) are measured relative to a wild-type reference strain (from ViroLogic). Protease genotypes are shown for both baseline and on-treatment samples with primary resistance substitutions underlined.